MINYANVILLE ORIGINAL Shares of Peregrine Pharmaceuticals (PPHM) jumped more than 500% over the past few months as investors await results of a mid-stage study testing its drug for lung cancer. That’s quite a comeback for a company that was in danger of being booted from the Nasdaq Stock Market in March because its price was so low. On Friday study data for Peregrine’s drug bavituximab will be presented at a medical meeting in Chicago. The results will be carefully scrutinized by the medical and investor communities and the data will determine the company’s next step which includes signing a ...